Jazz Pharmaceuticals II SASU

Jazz Pharmaceuticals II SASU

Jazz Pharmaceuticals II SASU

Date Founded



84, quai Charles de Gaulle,Lyon, Rhone-Alpes 69006

Type of Company



Commercial Scientific Research

Company Description

Alizé Pharma II SAS engages in the development of biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases. Its lead assets are pegcrisantaspase (Asparec), a PEGylated recombinant L-asparaginase from Erwinia chrysanthemi, and related intellectual property. The company was founded in 2008 and is headquartered in Ecully, France.

Board of Directors

President & Founder at Orega Biotech SAS

President at CEMA, Inc.

Paths to Jazz Pharmaceuticals II SASU
Potential Connections via
Relationship Science
Jazz Pharmaceuticals II SASU
Recent Transactions
Details Hidden

Jazz Pharmaceuticals Plc purchases Jazz Pharmaceuticals II SASU from Turenne Capital Partenaires SA, Octalfa SAS

Transaction Advisors
Legal Advisor

Advised onJazz Pharmaceuticals Plc purchases Jazz Pharmaceuticals II SASU from Turenne Capital Partenaires SA, Octalfa SAS

Details Hidden

CEMA, Inc. operates as an investment holding company. The company is headquartered in Montreal, Canada.

Details Hidden

Octalfa is a hands-on investor who plays an active role in their portfolio companies and seeks board representation. The firm focuses on early-stage businesses including seed-stage projects in the life sciences sectors, and may also co-invest in later-stage companies. Octalfa invests from their own balance sheet, in the EUR 500 thousand to 1.5 million range, as a one-time investor or over several financing rounds.

Details Hidden

Turenne Capital is an active, long-term manager which aims to provide equity capital to fund growth in fast-growing companies in the industrial innovation, services, health and retail sectors. The firm takes minority stakes in fast-growing companies, seeking to invest from €1-€5 million immediately or over an extended period.Turenne Capital partners with their investee companies, providing ongoing support to management in the form of industrial and financial expertise to assist with strategic decisions. They also facilitate access to their network of relationships, assist with future fund raising and prepare an optimum exit strategy for the investee company.The firm seeks to invest in growth companies with strong, experienced management and annual sales greater than €1 million and ideally between €10-€50 million. They look for profitable or near profitable companies with good prospects for international expansion and a distinctive and/or innovative market position.Turenne's Executive Committee, advised by an Investment Committee composed of private-equity professionals, entrepreneurs, strategy consultants and institutional investors, makes the firm's investment decisions.